Search: onr:"swepub:oai:DiVA.org:uu-505235" >
Reducing carbon foo...
Reducing carbon footprint by switching to reusable soft-mist inhalers
-
- Janson, Christer (author)
- Uppsala universitet,Lung- allergi- och sömnforskning
-
- Platz, Jaime Hernando (author)
- Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany.
-
- Soulard, Stephane (author)
- Boehringer Ingelheim bv, Amsterdam, Netherlands.
-
show more...
-
- Langham, Sue (author)
- Maverex Ltd, Newcastle Upon Tyne, Tyne & Wear, England.
-
- Nicholson, Lindsay (author)
- Maverex Ltd, Newcastle Upon Tyne, Tyne & Wear, England.
-
- Hartgers-Gubbels, Elisabeth Sophia (author)
- Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany.
-
show less...
-
(creator_code:org_t)
- 2023-03-16
- 2023
- English.
-
In: ERJ Open Research. - : European Respiratory Society (ERS). - 2312-0541. ; 9:3
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Objective: Inhalation therapy is the cornerstone of COPD, together with non-pharmacological treatments. Long-acting muscarinic antagonists (LAMAs), alone or in combination with long-acting beta-agonists (LABAs), are commonly used. Pressurised metered-dose inhalers (pMDIs), dry powder inhalers (DPIs) and soft-mist inhalers (SMIs) are used, each with different carbon footprints. This study aimed to assess the carbon footprint of hypothetically replacing LAMA or LAMA/LABA inhalers with an SMI, Respimat Reusable, within the same therapeutic class.Methods: An environmental impact model was established to assess the change in carbon footprint of replacing pMDIs/DPIs with Respimat Reusable within the same therapeutic class (LAMA or LAMA/LABA) across 12 European countries and the USA over 5 years. Inhaler use for country and diseasespecific populations was derived from international prescribing data and the associated carbon footprint (CO2 equivalents (CO(2)e)) was identified from published sources.Results: Over 5 years and across all countries, replacing LAMA inhalers with Spiriva Respimat Reusable reduced CO(2)e emissions by 13.3-50.9%, saving 93-6228 tonnes of CO(2)e in the different countries studied. Replacing LAMA/LABA inhalers with Spiolto Respimat Reusable reduced CO(2)e emissions by 9.5-92.6%, saving 31-50 843 tonnes of CO(2)e. In scenario analyses, which included total replacement of DPIs/pMDIs, consistent CO(2)e savings were estimated. Sensitivity analyses showed that results were sensitive to changes in several parameters including varying assumptions around reusability of inhalers and potential CO(2)e impact.Conclusion: Replacement of pMDIs and DPIs with Respimat Reusable within the same therapeutic class would result in substantial reductions in CO(2)e emissions.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Lungmedicin och allergi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Respiratory Medicine and Allergy (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database